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Abstract: Poor sleep quality is a common concern and a troublesome symptom among patients 
suffering from fibromyalgia. The purpose of this review was to identify and describe the available 
patient reported outcome measures (PROMs) of sleep quality validated in adult people diagnosed 
with fibromyalgia. The COSMIN and PRISMA recommendations were followed. An electronic 
systematized search in the electronic databases PubMed, Scopus, CINAHL Plus, PsycINFO, and ISI 
Web of Science was carried out. Validation studies of PROMs of sleep quality in fibromyalgia 
published in English or Spanish were included. The selection of the studies was developed through 
a peer review process through the online software “COVIDENCE”. The quality of the studies was 
assessed using the COSMIN Risk of Bias checklist. A total of 5 PROMs were found validated in 
patients with fibromyalgia: (1) Pittsburgh Sleep Quality Index (PSQI), (2) Jenkins Sleep Scale (JSS), 
(3) Sleep Quality Numeric Rating Scale (SQ-NRS), (4) Medical Outcomes Study-Sleep Scale (MOS-
SS), and (5) Fibromyalgia Sleep Diary (FSD). The quality of the evidence was very good and the 
quality of the results ranged from moderate to high. All the included PROMs, except for the FSD, 
showed adequate psychometric properties and, therefore, are valid and reliable tools for assessing 
sleep quality in the context of FM. However, none of the studies analyzed all the psychometric 
properties of the included PROMs as established in the COSMIN guidelines, highlighting that this 
is a potential field of research for future investigations. 
Keywords: patient-reported outcome measures; consensus-based standards for the selection of 
health measurement instruments; surveys and questionnaires; sleep quality; fibromyalgia; 
psychometrics; systematic review 
 
1. Introduction 
Historically, fibromyalgia (FM) has been presented as a heterogeneous health condition and a 
multitude of symptoms associated with it have been described, which has made it difficult to 
establish the most prevalent and severe symptoms of this syndrome [1]. Likewise, as stated by 
Carmona et al. [2], FM is a challenging health condition given the lack of objective tests to monitor 
the evolution of the people suffering from it. 
The OMERACT working group [3] established the central clinical domains that characterize FM 
using a Delphi study design that included physicians and patients. Their results showed a high level 
of agreement between professionals and patients that poor sleep quality is one of the main symptoms 
of FM. In addition, 92% of patients identified that the assessment of poor sleep quality should be 
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carried out in all experimental studies about FM. These results are in line with a previous internet 
survey, including 2596 people with FM [4], showing that poor sleep quality, together with pain, 
fatigue and morning stiffness, are the symptoms with greater severity and impact in these patients. 
Specifically, 79% of the participants perceived that sleep problems were one of the most common 
factors in the exacerbation of FM symptoms [4]. 
In terms of prevalence, the studies indicate that between 65% and 99% of people diagnosed with 
FM report poor sleep quality [5–7]. Other authors [8] state that 63% of these patients report two or 
more symptoms of difficulty sleeping, while only 11.2% report having no problem sleeping. A recent 
meta-analysis of case-control studies indicated that, in comparison with healthy controls, people with 
FM show significantly lower sleep efficiency and sleep quality, shorter sleep duration, longer wake 
time after sleep onset and more percentage of light sleep stages when assessed with 
polysomnography. Subjective assessment showed that patients with FM have more difficulties falling 
asleep and worse sleep efficiency. Therefore, and although there are no conclusive data regarding the 
prevalence of poor sleep quality in FM, the results presented reveal that it is a recurrent and a 
concerning symptom among these patients [9]. Furthermore, poor sleep quality has been shown to 
be related with increases in the intensity of pain, and it is an aggravating factor of other FM symptoms 
such as fatigue, cognitive problems and quality of life [7,10].  
Taking into account all these data, the assessment of sleep quality could guarantee 
comprehensive assistance in patients with FM and can provide important information on the 
effectiveness of prescribed treatments, both pharmacological and non-pharmacological [11]. In the 
field of research, the assessment of sleep quality may be of especial interest when evaluating the 
effectiveness of new treatments, and also to improve the knowledge on how this symptom can 
influence the general health status of people who suffer from FM [10].  
Therefore, the main objective of this systematic review was to identify and describe the available 
PROMs of sleep quality in adults diagnosed with FM and their psychometric properties. In addition, 
adaptations and translations of these tools to other languages were also presented. 
2. Materials and Methods 
This review was carried out following the “COnsensus-based Standards for the selection of 
health Measurement Instruments” (COSMIN) [12] and the “Preferred Reporting Items for Systematic 
reviews and Meta-Analyses” (PRISMA) [13] guidelines. 
The review protocol was registered with PROSPERO (Record ID = CRD42018114218).  
2.1. Criteria for Considering Studies for This Review 
2.1.1. Type of Studies 
Validation or cross-cultural adaptation studies published in English or Spanish (the research 
team did not speak fluently other languages) with no restriction regarding the year of publication. 
Additionally, the development studies for each of the included PROMs were searched so as to 
analyze the content validity for those PROMs originally developed in the context of FM. In the case 
of the PROMs that were developed for other target populations, the report was also searched and the 
results presented.  
2.1.2. Type of Participants 
Validation or cross-cultural adaptation studies involving adult participants (18 years or older) 
diagnosed with FM. 
2.1.3. Type of Outcome Measures 
Studies that met the above inclusion criteria were included regardless of whether they did not 
report all the psychometric properties established in the COSMIN guidelines [12]: content validity, 
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structural validity, internal consistency, cross-cultural validity, reliability, measurement error, 
criterion validity, hypotheses testing for construct validity, and responsiveness. 
2.2. Search Strategy 
An electronic systematized search in the electronic databases PubMed, Scopus, CINAHL Plus, 
PsycINFO, and ISI Web of Science was carried out. 
The search strategy was developed by two authors (RP and AM) based on the COSMIN “search 
filters for finding studies on measurement properties” provided as an additional tool in the COSMIN 
website (https://www.cosmin.nl/tools/pubmed-search-filters/). The Peer Review of Electronic Search 
Strategies guidelines [14] recommendations were also implemented for the development of the 
search strategy in the selected databases. The following MeSH terms were used for the development 
of the search strategy: “Fibromyalgia”, “Sleep”, “Surveys and Questionnaires”, “Psychometrics”, and 
“Validation Studies as Topic”. Entry terms and free text terms derived from or related with each 
selected MeSH term were also included in the search strategy (Appendix A: “search strategy from 
the consulted databases”).  
The last search was run on March the 6th, 2020. 
Searching other sources: a manual search of studies was carried out based on the bibliographic 
references of the included articles.  
2.3. Selection of Studies 
The selection of studies process was developed with the online software “COVIDENCE”. The 
identified studies were first stored and checked for duplicates. After duplicates were removed and 
based on the inclusion criteria, two authors (CC and AM) carried out first the title and abstract 
screening, and subsequently the full-text screening of the studies through a peer review process. In 
case of discrepancy in any of the two phases of the selection of the studies, a third author (MG) 
discussed the suitability of the studies to be included. 
2.4. Data Collection and Data Items 
The data collection process was carried out by two authors (CC and AM) independently, and a 
third author (FV) reviewed the extraction so as to ensure accuracy of the data. 
For each of the included PROMs, the following data items were extracted in accordance with the 
COSMIN recommendations [12]: characteristics of the included PROMs, characteristics of the 
included study populations, results of studies on measurement properties.  
2.5. Risk of Bias and Quality of the Results Assessment 
Two authors (CC and FV) rated independently the RoB of each of the included studies and the 
quality of the results following the COSMIN RoB checklist [15]. A third author (MG) intervened in 
case of discrepancy. The COSMIN RoB is comprised by ten checklists evaluating the following 
methodological aspects: (1) PROM development, (2) Content validity, (3) Structural validity, (4) 
Internal consistency, (5) Cross-cultural validity/Measurement invariance, (6) Reliability, (7) 
Measurement error, (8) Criterion validity, (9) Hypotheses testing for construct validity, and (10) 
Responsiveness. Each of the checklists includes different items that can be rated as “very good”, 
“adequate”, “doubtful”, “inadequate”, and “not applicable”. An excel document is provided on the 
COSMIN website to facilitate the RoB assessment (https://www.cosmin.nl/tools/guideline-
conducting-systematic-review-outcome-measures/?portfolioCats=19).  
The quality of the results was evaluated after the data extraction regarding the measurement 
properties of each of the included PROM in accordance with the COSMIN pre-established criteria 
[12,16] (more details in Table 1). 
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Table 1. Criteria for evaluation of the quality of results. 
Measurement Property Rating Criteria 
Structural Validity 
+ 
CTT 
CFA: CFI or TLI or comparable measure >0.95 OR RMSEA < 0.06 
OR SRMR < 0.08a 
IRT/Rasch 
No violation of unidimensionality b: CFI or TLI or comparable 
measure > 0.95 OR RMSEA < 0.06 OR SRMR < 0.08 
AND 
no violation of local independence: residual correlations among 
the items after controlling for the dominant factor < 0.20 OR Q3s 
< 0.37 
AND 
no violation of monotonicity: adequate looking graphs OR item 
scalability > 0.30 
AND 
adequate model fit 
IRT: χ2 > 0.001 
Rasch: infit and outfit mean squares ≥ 0.5 and ≤ 1.5 OR Z-
standardized values > −2 and < 2 
? 
CTT: not all information for ‘+’ reported  
IRT/Rasch: model fit not reported 
− Criteria for ‘+’ not met 
Internal Consistency 
+ 
At least low evidence c for sufficient structural validity d AND 
Cronbach’s alpha(s) ≥ 0.70 for each unidimensional scale or 
subscale e 
? 
Criteria for “At least low evidence c for sufficient structural 
validity d” not met 
− 
At least low evidence c for sufficient structural validity d AND 
Cronbach’s alpha(s) < 0.70 for each unidimensional scale or 
subscale e 
Reliability 
+ ICC or weighted Kappa ≥ 0.70 
? ICC or weighted Kappa not reported 
− ICC or weighted Kappa < 0.70 
Measurement Error 
+ SDC or LoA < MIC d 
? MIC not defined 
− SDC or LoA > MIC d 
Hypotheses Testing for 
Construct Validity 
+ The result is in accordance with the hypothesis f 
? No hypothesis defined (by the review team) 
− The result is not in accordance with the hypothesis f 
Cross-Cultural 
Validity/Measurement 
Invariance 
+ 
No important differences found between group factors (such as 
age, gender, language) in multiple group factor analysis OR no 
important DIF for group factors (McFadden’s R2 < 0.02) 
? No multiple group factor analysis OR DIF analysis performed 
− Important differences between group factors OR DIF was found 
Criterion Validity 
+ Correlation with gold standard ≥ 0.70 OR AUC ≥ 0.70 
? Not all information for ‘+’ reported 
− Correlation with gold standard < 0.70 OR AUC < 0.70 
Responsiveness 
+ The result is in accordance with the hypothesis f OR AUC ≥ 0.70 
? No hypothesis defined (by the review team) 
− 
The result is not in accordance with the hypothesis f OR AUC < 
0.70 
Developed by Abedi, Prinsen, Shah, Buser and Wang [16], based on Prinsen et al. [12] under a Creative 
Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/). AUC 
area under the curve, CFA confirmatory factor analysis, CFI comparative fit index, CTT classical test 
theory, DIF differential item functioning, ICC intraclass correlation coefficient, IRT item response 
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theory, LoA limits of agreement, MIC minimal important change, RMSEA root mean square error of 
approximation, SEM standard error of measurement, SDC smallest detectable change, SRMR 
standardized root mean residuals, TLI Tucker–Lewis index, + sufficient, − insufficient, ? 
indeterminate. a To rate the quality of the summary score, the factor structures should be equal across 
studies; b Unidimensionality refers to a factor analysis per subscale, while structural validity refers to 
a factor analysis of a (multidimensional) patient-reported outcome measure; c As defined by grading 
the evidence according to the GRADE approach; d This evidence may come from different studies; 
e The criteria “Cronbach alpha < 0.95” was deleted, as this is relevant in the development phase 
of a PROM and not when evaluating an existing PROM; f The results of all studies should be taken 
together, and it should then be decided if 75% of the results are in accordance with the hypotheses. 
2.6. Data Analysis and Synthesis of Results 
A narrative synthesis of the results was carried out.  
3. Results 
3.1. Study Selection 
The electronic literature search yielded 3042 records in total and 1410 duplicates were removed. 
During the process of study selection, 1632 records were analyzed by title and abstract, and 1620 were 
excluded. Finally, 12 records were selected for the full text analysis, and 6 studies met the inclusion 
criteria. The manual search based on the bibliographic references of the included studies yielded one 
study. Therefore, seven studies were included in the narrative synthesis and five instruments were 
described (Figure 1: Process of Study Selection (PRISMA Flow Diagram) [13].) 
 
Figure 1. Process of Studies Selection (PRISMA Flow Diagram). 
  
Int. J. Environ. Res. Public Health 2020, 17, 2992 6 of 27 
3.2. Risk of Bias 
All the included studies [17–23] showed a very good methodological quality for assessing the 
measurement properties of the selected PROMs in accordance with the COSMIN criteria. Therefore, 
the RoB was rated as low for all the studies. The results from the risk of bias assessment can be 
consulted in Table 2. 
Table 2. Risk of Bias assessment. 
PROM 
Measurement 
Properties Assessed 
Risk of Bias 
PSQI 
Internal Consistency Low 
Reliability Low 
Structural validity Low 
Hypothesis testing Low 
JSS 
Internal Consistency Low 
Reliability Low 
Structural validity Low 
Responsiveness Low 
SQ-NRS 
Content validity Low 
Reliability Low  
Hypothesis testing Low 
MOS-SS 
Content validity Low 
Internal Consistency Low 
Reliability Low 
FSD Content validity Low 
PSQI: Pittsburgh Sleep Quality Index, JSS: Jenkins Sleep Scale, SQ-NRS: Sleep Quality-Numeric 
Rating Scale, MOS-SS: Medical Outcomes Study-Sleep Scale, FSD: Fibromyalgia Sleep Diary. 
3.3. Characteristics of the Included PROMs and the Study Populations 
The characteristics of the included PROMs and the characteristics of the study populations can 
be consulted in Tables 3 and 4, respectively.  
The included studies reported the following PROMs for sleep quality in patients with FM: (1) 
Pittsburgh Sleep Quality Index, (2) Jenkins Sleep Scale (alternative scoring method), (3) Sleep Quality-
Numeric Rating Scale, (4) Medical Outcomes Study-Sleep Scale, and (5) Fibromyalgia Sleep Diary. 
For those of the included PROMs that were not originally developed as specific tools for 
assessing sleep quality in patients with FM, the characteristics of the PROM and the study 
populations of the original development studies were also included in Tables 3 and 4.  
3.3.1. Pittsburgh Sleep Quality Index (PSQI) 
The PSQI was developed with the understanding that the essential elements that characterize 
good sleep are mainly subjective and may vary between individuals. Accordingly, Buysse et al. [24], 
pointing out that poor sleep quality was a highly prevalent problem in people with psychiatric 
problems, developed the first version of this index in 1989 with the objective of assessing in a reliable 
and valid way the quality of sleep from the perspective of patients. 
Objective of the tool [24]: The PSQI assesses the sleep quality of the month prior to the evaluation 
since, as the authors stated in the “Consensus Conference of Insomnia, 1984,” it was established that 
the assessment of 2–3 weeks of sleep is the ideal minimum time for being able to discern between 
transient and persistent sleep problems. Accordingly, the PSQI allows the latter distinction to be 
made if it is applicable twice with one month of separation.  
Number of items and response options [24]: To assess the described components, the PSQI is 
composed of 19 self-rated questions and 5 questions that are answered by the roommate or bedmate, 
although the latter are only used for clinical purposes and are not included in the final score. The 
items of the PSQI are organized into seven components: (1) Subjective sleep quality, (2) Sleep latency, 
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(3) Sleep duration, (4) Habitual sleep efficiency, (5) Sleep disturbances, (6) Use of sleeping medication, 
and 7) Daytime dysfunction. The first four items are answered by providing some data related to the 
usual time of sleep, time to fall asleep, time awake at night, and hours of sleep per night. The other 
12 items to be filled out by the patient plus the items to be filled in by the roommate or bed partner 
use the previous set of answers, and the respondent is asked to mark an X for the option that most 
corresponds to their experience. There are four possible answers, for example: (1) Not during the past 
month, (2) Less than once a week, (3) Once or twice a week, or (4) Three or more times a week. In one 
of the items, the possible answers are: (1) Very good, (2) Fairly good, (3) Fairly bad or (4) Very bad. 
Another item has the following answers: (1) No problem at all, (2) Only a very slight problem, (3) 
Somewhat of a problem, or (4) A very big problem. Finally, the last question has also four possible 
answers: (1) No bed partner or roommate, (2) Partner/roommate in other room, (3) Partner in the 
same room, but not same bed, or (4) Partner in the same bed. 
Administration method and time of response [24]: The PSQI is self-completed by the respondent, 
and it takes 5–10 min to complete the questionnaire.  
Scoring: The total score of the questionnaire is derived from the sum of the seven components of 
the questionnaire. Each of the items has, as explained above, four possible answers, so the scoring varies 
between 0 and 3. In this way, the maximum final score is 21 points and the minimum score is 0. 
Score interpretation [24]: According to the authors, a score lower than 5 points would indicate 
that the respondent is a “good sleeper” while ratings greater than 5 points would be indicative of 
poor sleep quality and moderate difficulties in three components or serious difficulties in at least two 
components of the seven that are evaluated. 
Method of development [24]: The PSQI was developed based on the clinical experience of the 
authors with patients with sleep disorders and the results of a review of the previous literature 
through which the authors identified the already developed tools for the assessment of sleep quality. 
This process ensured that prior to the development of the PSQI, there were already different sleep 
measurement tools. However, there were very few that had been developed with clinical subjects. In 
addition, the PSQI allows the assessment of the sleep quality of the previous month, unlike other 
scales that only permit the assessment of the previous night or sleep problems during the year prior 
to the evaluation. 
The authors defined four objectives [24]: (1) to develop a standardized, reliable, and valid tool 
to assess the quality of sleep, (2) to differentiate good and bad sleepers, (3) to develop an easy-to-
complete and easy-to-interpret tool, and (4) to develop a short and clinically useful tool to assess a 
series of sleep problems that can interfere with the quality of it. 
For the development of the PSQI, the authors recruited a sample composed of 52 healthy subjects 
defined as “good sleepers”, who formed control group I; 34 patients admitted to or outpatients of a 
psychiatric center diagnosed with major depressive disorder and considered “bad sleepers” who 
formed group II; and finally, 62 patients with sleep disorders referred by a physician from another 
psychiatric center formed group III. 
After the development of the PSQI, an 18-month field testing was carried out to assess the clinical 
experience of its use. 
Translations/adaptations in patients with FM: According to the results of our review, the PSQI was 
also validated in a sample of people diagnosed with FM in Spain [17] (more details in Tables 3 and 4).  
3.3.2. Jenkins Sleep Scale (JSS) 
The development of the JSS was based on the absence of brief and easy-to-use sleep evaluation 
scales in the field of epidemiological research. In addition, the available tools only allowed the 
assessment of very specific sleep conditions. Thus, the main objective of the JSS was not to serve as a 
tool for assessing specific sleep problems such as narcolepsy or sleep apnea, but to allow evaluation 
of the most common symptoms in the general population [25]. 
Objective of the tool [25]: The JSS permits the assessment of the most common symptoms of 
insomnia (difficulty falling asleep and maintaining sleep, as well as the sensation of fatigue upon 
awakening) during the previous month. 
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Number of items and response options [25]: The scale consists of four items: (1) Do you have 
trouble falling sleep? (2) Do you wake up several times per night? (3) Do you have trouble staying 
asleep? (including waking far too early), and (4) Do you wake up after your usual amount of sleep 
feeling tired and worn out? 
Each of the items is classified on a Likert scale of 6 points based on the frequency with which the 
respondent experiences each of the evaluated symptoms (0 = not at all, 1 = 1–3 days, 2 = 4–7 days, 3 = 
8–14 days, 4 = 15–21 days, and 5 = 22–31 days).  
Administration method and time of response [25]: The JSS is a self-administered, brief, and 
quick-filling scale. 
Scoring: According to the response options previously presented, the results of the JSS can vary 
from 0 to 20 in the total sum of the items. 
Score interpretation [25]: 0 points are indicative that there are no sleep problems and 20 points 
indicate significant sleep problems. 
Method of development [25]: The scale was developed within the framework of two other larger 
projects, the “Air Traffic Controller (ATC) Health Change Study” and the “Recovery Study” (RS). In 
the former, 300 questionnaires were sent by post, of which 250 were completed and returned. The 
sample consisted mainly of men between 25 and 49 years of age and the average age of respondents 
was 37.1 years. In the case of the RS, 467 subjects admitted for cardiac valve surgery or coronary 
bypass were included. A total of 80% of the sample consisted of white men between the age of 25–69 
years, although most were between 50 and 60 years old. 
Although the JSS was used for both studies, in the ATC study, all four items that make up the 
scale were included, but in the RS the item “waking up several times per night” was omitted, and the 
last two categories of responses were also modified and grouped into one, so that the last answer 
option was “15–31 days” and the total score could range between 0 and 12 points. 
In the ATC study, the scale was administered only once, while in the RS study, it was completed 
before the surgery and at 6 and 12 months after the same. 
Translations/adaptations in patients with FM: Crawford et al. [18] validated a JSS version with 
an alternative method of scoring in a sample of patients diagnosed with FM. The authors 
hypothesized that using a scoring method in which the patients must recall the exact number of 
nights they had sleep disturbance could increase the likelihood of incurring a recall bias. Therefore, 
an alternative scoring method was proposed in which the respondent must select a period of time 
instead of an exact number of days: (1) not at all (score = 0), (2) less than half the time (score = 1), and 
(3) greater than half the time (score = 2). Hence, the total score ranges from 0 to 8, higher scores being 
indicative of greater severity of sleep problems (more details in Tables 3 and 4). 
3.3.3. Sleep Quality-Numeric Rating Scale (SQ-NRS) 
The Sleep SQ-NRS was developed in order to collect relevant and appropriate information for a 
generic approach to the global impact of sleep problems in patients with FM [19].  
Objective of the tool: The NRS is eligible in evaluations that require a daily record of the quality 
of sleep, offering the patient an element with little time burden. 
Number of items and response options [19]: It is a tool with a single element. The patient is asked 
to choose the one that best describes their sleep quality during the last 24 h on a numerical scale of 11 
points (0–10). 
Administration method and time of response [19]: Self-managing scale and quick response. The 
patient is instructed to complete the tool just after waking up. 
Scoring and score interpretation: The scoring scale fluctuates in a range between 0 “best possible 
sleep” and 10 “worst possible sleep”. 
Translations/adaptations in patients with FM: no validations were found in other languages. 
3.3.4. Medical Outcomes Study-Sleep Scale (MOS-SS)  
The development of the MOS-SS was derived from the results of a larger research project called 
the Medical Outcomes Study (MOS) [26], which consisted of a longitudinal descriptive observational 
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study linked to the health outcomes in patients with chronic diseases. In this study, the authors 
concluded that sleep is a key factor for the functionality and well-being of people with chronic health 
conditions. In addition, the authors stated that sleep assessment could be key to understanding the 
health problems associated with chronic health conditions and developing more effective treatments. 
Objective of the tool: The MOS-SS allows the assessment of sleep quality. 
Number of items and response options [1,27]: The MOS-SS is composed of 12 items that evaluate 
6 sleep domains: initiation (time to fall asleep), quantity (hours of sleep each night), maintenance, 
respiratory problems, perceived adequacy, and drowsiness. 
The sleep scale uses a wide variety of response sets. The first item: (1) 0–15 min, (2) 16–30 min, 
(3) 31–45 min, (4) 46–60 min, (5) More than 60 min. The second item is an open question allowing a 
response that ranges from 0–24 h. The remaining 10 items use a set of 6-point answers based on the 
following values: (1) All of the time, (2) Most of the time, (3) A good bit of the time, (4) Some of the 
time, (5) A little of the time, (6) None of the time. 
There is a nine-item version of the MOS-SS, named Sleep Problems Index II, and a 6-item version 
defined as the Sleep Problems Index I. Neither of the scales excludes any item from the original scale, 
but rather groups them in unique items so that the only difference is that these two scales are shorter. 
Administration method and time of response [20]: The MOS-SS is a self-administered scale and 
takes about 2–3 min to complete. 
Scoring [19]: Each of the response options described above is accompanied by a numerical index. 
The sum of the scores of the items and domains becomes a numerical scale of 0–100 in all the items. Two 
exceptions are contemplated: the score of the item “quantity” ranges between 0–24 and the score of the 
item “adequacy of sleep” ranges between 0–1. Regarding the interpretation of the score, higher scores 
indicate greater affectation of the variable that is being measured. In relation to sleep maintenance, it is 
considered optimal if the patient reports 7–8 h of sleep, assessed as 1, otherwise the score is 0. 
Score interpretation [1]: According to the authors, high scores indicate worse sleep problems. 
The exceptions are the items “sufficiency of sleep” and “quantity” where lower scores indicate worse 
sleep problems. 
Translations/adaptations in patients with FM: According to the results of this systematic review, 
there are three studies evaluating the content validity [19], the psychometric properties [20] and the 
test–retest reliability [21] of the MOS-SS in patients with FM (more details in Tables 3 and 4). 
3.3.5. Fibromyalgia Sleep Diary (FSD) 
Objective of the tool: In contrast with the above presented PROMs, the FSD was the first tool 
originally developed for evaluating sleep quality in people diagnosed with FM on a daily basis [23].  
Number of items and response options [23]: The FSD is composed of eight items: (1) How 
difficult was it to fall asleep last night? (2) How restless was your sleep last night?, (3) How difficult 
was it to get comfortable last night?, (4) How difficult was it to stay asleep last night?, (5) How deep 
was your sleep last night?, (6) How rested were you when you woke up for the day?, (7) How difficult 
was it to begin your day?, (8) Did you have enough sleep last night?. The response options are based 
on a numerical scale of 11 points ranging from 0 to 10. 
Score and score interpretation [23]: not reported.  
Method of development [23]: The FSD was developed by Kleinman et al. [23] in 2014 through a 
multi-staged process including a review of the literature, different qualitative approaches with 
experts and patients such as semi-structured interviews and focus groups, development of the 
conceptual framework and the first version of the FSD, and cognitive interviews so as to analyze the 
content validity and comprehensiveness of the PROM. The psychometric properties of the FSD were 
not analyzed. 
For the development of the items, the authors used the terminology that emerged from the focus 
groups with the patients so as to ensure the adequacy of the content to people diagnosed with FM.  
Translations/adaptations in patients with FM: no validations were found in other languages. 
 
Int. J. Environ. Res. Public Health 2020, 17, 2992 11 of 27 
Int. J. Environ. Res. Public Health 2020, 17, 2992; doi:10.3390/ijerph17092992 www.mdpi.com/journal/ijerph 
Table 3. Characteristics of the included PROMs. 
PROM * 
(Reference 
to First 
Article) 
Construct(s) 
Target 
Population 
Mode of 
Administration 
(e.g., Self-
Report, 
Interview-
Based, 
Parent/Proxy 
Report etc.) 
Recall 
Period 
(Sub)scale(s) 
(Number of 
Items) 
Response Options Range of Scores/Scoring 
Original 
Language 
Available 
Translations 
Pittsburgh 
Sleep 
Quality 
Index [24] 
Sleep 
Quality 
Patients 
diagnosed with 
major 
depressive 
disorder 
Self-completed 
by the 
respondent 
One 
month 
Subscales: (1) 
subjective sleep 
quality, (2) sleep 
latency, (3) sleep 
duration, (4) 
habitual sleep 
efficiency, (5) 
sleep disturbances, 
(6) use of sleeping 
medication, and 
(7) daytime 
dysfunction. 
Items: 19 self-rated 
questions and 5 
questions that are 
answered by the 
roommate or 
bedmate 
The first four items are answered 
by providing some data related 
to the usual time of sleep, time 
to fall asleep, time awake at 
night, and hours of sleep per 
night. The other 12 items to be 
filled out by the patient plus the 
items to be filled in by the 
roommate or bed partner use the 
previous set of answers, and the 
respondent is asked to mark an 
X for the option that most 
corresponds to their experience: 
(1) Not during the past month, 
(2) Less than once a week, (3) 
Once or twice a week, or (4) 
Three or more time a week. In 
one of the items the possible 
answers are: (1) Very good, (2) 
Fairly good, (3) Fairly bad or (4) 
Very bad. Another item has the 
following answers: (1) No 
problem at all, (2) Only a very 
slight problem, (3) Somewhat of 
a problem, or (4) A very big 
problem. Finally, the last 
question has also four possible 
answers: (1) No bed partner or 
roommate, (2) Partner/roommate 
The total score of the 
questionnaire is derived 
from the sum of the seven 
components of the 
questionnaire. Each of the 
items has, as explained 
above, four possible 
answers, so the scoring 
varies between 0 and 3. In 
this way, the maximum 
final score is 21 points and 
the minimum score is 0. 
a score lower than 5 points 
would indicate that the 
respondent is a “good 
sleeper” while ratings 
greater than 5 points 
would be indicative of 
poor sleep quality and 
moderate difficulties in 
three components or 
serious difficulties in at 
least two components of 
the seven that are 
evaluated. 
English 
Spanish with 
a sample of 
people 
diagnosed 
with FM [17] 
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in other room, (3) Partner in the 
same room, but not same bed, or 
(4) Partner in the same bed. 
Jenkins Sleep 
Scale [25] 
Symptoms 
of insomnia 
Patients 6 
months after 
cardiac surgery 
Air traffic 
controllers 
Self-
administered 
One 
month 
The scale consists 
of four items: (1) 
Do you have 
trouble falling 
sleep? (2) Do you 
wake up several 
times per night? 
(3) Do you have 
trouble staying 
asleep? (Including 
waking far too 
early), and (4) Do 
you wake up after 
your usual 
amount of sleep 
feeling tired and 
worn out? 
Each of the items is classified on 
a Likert scale of 6 points based 
on the frequency with which the 
respondent experiences each of 
the evaluated symptoms (0 = not 
at all, 1 = 1–3 days, 2 = 4–7 days, 
3 = 8–14 days, 4 = 15–21 days, 
and 5 = 22–31 days). 
According to the response 
options previously 
presented, the results of 
the JSS can vary from 0 to 
20 in the total sum of the 
items. 
0 points are indicative that 
there are no sleep 
problems and 20 points 
indicate significant sleep 
problems. 
English  
An 
alternative 
scoring 
method for 
the JSS was 
validated in 
Spanish with 
a sample of 
people 
diagnosed 
with FM [18]. 
Sleep 
Quality 
Numeric 
Rating Scale 
[19] 
Sleep 
Quality 
People 
diagnosed with 
FM 
Self-
administered 
Daily 
record 
of the 
quality 
of sleep 
It is a tool with a 
single element. 
The patient is 
asked to choose 
the one that best 
describes their 
sleep quality 
during the last 24 
h on a numerical 
scale.  
A numerical scale of 11 points 
(0–10). 
The scoring scale 
fluctuates in a range 
between 0 “best possible 
sleep” and 10 “worst 
possible sleep”. 
English - 
Medical 
Outcomes 
Study-Sleep 
Scale 
[1,19,20,27] 
Sleep 
quality and 
quantity 
Healthy adults 
and adults 
diagnosed with 
neuropathic 
pain 
Self-
administered 
One 
month 
The MOS-SS is 
composed of 12 
items that evaluate 
six sleep domains: 
initiation (time to 
fall asleep), 
quantity (hours of 
sleep each night), 
maintenance, 
respiratory 
The first item: (1) 0–15 min, (2) 
16–30 min, (3) 31–45 min, (4) 46–
60 min, (5) More than 60 min. 
The second item is an open 
question allowing a response 
that ranges from 0–24 h. The 
remaining ten items use a set of 
6-point answers based on the 
following values: (1) All of the 
time, (2) Most of the time, (3) A 
According to the authors, 
high scores indicate worse 
sleep problems. The 
exceptions are the items 
“sufficiency of sleep” and 
“quantity” where lower 
scores indicate worse sleep 
problems. 
English 
English with 
a sample of 
people 
diagnosed 
with FM [19–
21] 
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problems, 
perceived 
adequacy, and 
drowsiness. 
good bit of the time, (4) Some of 
the time, (5) A little of the time, 
(6) None of the time. 
Fibromyalgia 
Sleep Diary 
[23] 
Sleep 
quality 
People 
diagnosed with 
FM 
Self-
administered 
Daily 
record 
of the 
quality 
of sleep 
The FSD consist of 
eight items: (1) 
How difficult was 
it to fall asleep last 
night?, (2) How 
restless was your 
sleep last night?, 
(3) How difficult 
was it to get 
comfortable last 
night?, (4) How 
difficult was it to 
stay asleep last 
night?, (5) How 
deep was your 
sleep last night?, 
(6) How rested 
were you when 
you woke up for 
the day?, (7) How 
difficult was it to 
begin your day?, 
and (8) Did you 
have enough sleep 
last night? 
A visual analogue scale of 11 
points ranging from 0 to 10. 
Not provided English - 
*Patient-Reported Outcome Measure 
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Table 4. Characteristics of the study populations. 
  Population Disease Characteristics Instrument Administration  
PROM Ref N 
Age 
Mean (SD, 
Range) yr 
Gender 
% Female 
Disease 
Disease 
Duration 
Mean (SD) yr 
Disease Severity Setting Country Language 
Response 
Rate 
Pittsburgh Sleep 
Quality Index 
24 
Sample 1 
= 34 
Sample 2 
= 45 
Sample 3 
= 17 
Sample 4 
= 52 
Sample 1: 
50.9 (range: 
21–80) 
Sample 2: 
44.8 (range: 
20–80) 
Sample 3: 
42.2 (range: 
19–57) 
Sample 4: 
59.9 (range: 
24–83) 
Sample 1: 
26.4% 
Sample 2: 
64.4% 
Sample 3: 
52.9% 
Sample 4: 
23.07% 
Sample 1: Major 
depressive disorder 
Sample 2: Disorder of 
Initiating and 
Maintaining Sleep 
Sample 3: Disorders of 
Excessive Somnolence 
Sample 4: Healthy 
subjects 
- - 
Psychiatric  
Clinics 
United 
States of 
America 
English 93.67% 
 17 138 52.83 (±9.32) 
100% 
women 
Fibromyalgia 
15.77 years (± 
9.76) 
Moderate:  
FIQ < 70  
N = 68 
FIQ score (51.02 ± 
16.28) 
Severe:  
FIQ ≥ 70 
N = 70 
FIQ score (80.44 ± 
6.20) 
Community (FM 
association) 
Spain Spanish 
Test: 100% 
Retest: 
69.56% 
Jenkins Sleep Scale 25 
Sample 1 
= 300 
Sample 2 
= 467 
Sample 1: 
37.1 
(25–49) 
Sample 2: 
54.9 (25–69) 
Sample 1: 
0% 
Sample 2: 
20% 
Sample 1: Air Traffic 
Controllers  
Sample 2: Cardiac 
valve surgery or 
coronary bypass 
Sample 1: -  
Sample 2: - 
Sample 1: -  
Sample 2; - 
Sample 1: 
community  
Sample 2: 
Secondary health 
care 
United 
States of 
America 
English 
Sample 1: 
83.33% 
Sample 2:  
Test: 100% 
Retest: 
91.22% 
 18 195 46.5 (±11.35) 94.4% Fibromyalgia ∼9 years - 
Clinical setting 
(unspecified) 
United 
States of 
America 
English 97.95% 
Sleep Quality 
Numeric Rating 
Scale 
20 
Sample 1 
= 748 
Sample 1: 
48.8 (±10.9) 
Sample 1: 
94.4% 
Fibromyalgia 
Sample 1: ∼9 
years 
Mean pain score 
(0–10) 
Clinical setting 
(unspecified) 
United 
States of 
America 
English - 
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Sample 2 
= 745 
Sample 2: 
50.1 (± 11.4) 
Sample 2: 
94.5% 
Sample 2: ∼10 
years 
Sample 1: 7.1 (± 
1.3) 
Sample 2: 6.7 (± 
1.3) 
 19 20 50.3 (29–64) 80% Fibromyalgia 8.9 (−1–18) 
Pain level (0–10) 
(SD) 
6 (1.6) 
Community 
United 
States of 
America 
English  
Medical Outcomes 
Study Sleep Scale 
27 
Sample 1 
= 1011 
Sample 2 
= 173 
Sample 1: 46 
(18–94 range) 
Sample 2: 72 
(31–100 
range) 
Sample 1: 
51% 
Sample 2: 
53% 
Sample 1: Healthy 
subjects 
Sample 2: Postherpetic 
neuralgia 
Sample 1: - 
Sample 2: 33.8 
months (35.9) 
- 
Clinical Setting 
(unspecified) 
United 
States of 
America 
English 
Sample 1: - 
Sample 2:  
Test: 100% 
Re-test: 
51.44% 
 19 20 50.3 (29–64) 80% Fibromyalgia 8.9 (-1–18) 
Pain level (0–10) 
(SD) 
6 (1.6) 
Community 
United 
States of 
America 
English  
 20 
Sample 1: 
748 
Sample 2: 
745 
Sample 1: 
48.8 (± 10.9) 
Sample 2: 
50.1 (± 11.4) 
Sample 1: 
94.4% 
Sample 2: 
94.5% 
Fibromyalgia 
Sample 1: ∼9 
years 
Sample 2: ∼10 
years 
Mean pain score 
(0–10) 
Sample 1: 7.1 (± 
1.3) 
Sample 2: 6.7 (± 
1.3) 
Clinical setting 
(unspecified) 
United 
States of 
America 
English - 
 21 129 49.4 (± 11.0) 91.3% 
Fibromyalgia 
 
≥ 2 years 
Moderate-to-
severe in 88.1% of 
the sample 
Community 
United 
States of 
America 
English 100% 
Fibromyalgia 
Sleep Diary 
24 
FM 
experts = 
4 
FM 
patients = 
34 
FM patients: 
47.8 (± 11.9) 
FM 
patients:  
88.2% 
Fibromyalgia Not reported Not reported 
Community-
based clinical 
sites 
United 
States of 
America 
English 100% 
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3.4. Results of Studies on the Measurement Properties in People Diagnosed with FM 
None of the included studies reported all the measurement properties established by the 
COSMIN guidelines [12]. 
For the PSQI, the authors [17] reported data regarding internal consistency, reliability and 
hypotheses testing and were rated as positive (more details in Table 5: Results of studies on 
measurement properties (PSQI)). 
The reported measurement properties for the JSS with an alternative scoring method [18] were 
internal consistency, criterion validity, test–retest reliability, and responsiveness. The results from 
internal consistency and responsiveness were rated as positive, while structural validity, criterion 
validity and reliability obtained moderate quality of the results, as some of them did not achieve the 
minimum standards established by the COSMIN guidelines [12] (more details in Table 6. Results of 
studies on measurement properties (JSS)).  
The SQ-NRS content validity was evaluated by Martin et al. [19], showing favorable results for 
patients with FM. Cappelleri et al. [22] analyzed the criterion validity, the test–retest reliability and 
the responsiveness of the SQ-NRS showing positive results (more detail in Table 7. Results of studies 
on measurement properties (SQ-NRS)). 
Regarding the MOS-SS, the results obtained by Martin et al. [19] provided strong evidence for 
validating the content of the tool in people diagnosed with FM. Cappelleri et al. [20] reported the 
structural validity and the internal consistency of the MOSS-SS, while the 1-week reliability of the 
scale was assessed by Sadosky et al. [21]. The results were positive for the internal consistency and 
for the reliability. However, the structural validity was rated as negative (more details in Table 8. 
Results of studies on measurement properties (MOS-SS)). 
Additionally, Cappelleri et al. [20] estimated that a change of 7.9 of the total score represents the 
minimal clinical important change of the MOS-SS. 
In relation to the FSD, the included study [23] aimed to develop and to analyze the content 
validity of the tool through a qualitative approach. The qualitative results showed that the FSD 
strongly represents the elements of sleep quality as a construct in the context of FM. As the 
psychometric evaluation of the FSD was not performed there were no statistical data to summarize.  
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Table 5. Results of studies on measurement properties (PSQI). 
PROM (Ref) 
Country (Language) in 
Which the PROM Was 
Evaluated 
Internal Consistency Test–Retest Reliability Hypotheses Testing 
n 
Meth 
Qual 
Result 
(Rating) 
n 
Meth 
Qual 
Result (Rating) n 
Meth 
Qual 
Result (Rating) 
Pittsburgh Sleep 
Quality Index [17] 
Spain (Spanish) 138 + α = 0.805 96 + 
ρ = 0.806 for the PSQI total score (p < 0.001). Lowest value 
ρ = 0.356 “daytime dysfunction” Highest value ρ = 0.718 
“use of sleeping medication” 
96 + 
FIQ (total score) ρ = 
0.304 (p < 0.01) 
SF-36 
Physical functioning 
ρ = −0.372 (p < 0.01) 
Role physical ρ = 
−0.217 (p < 0.05) 
Role emotional ρ = 
−0.254 (p < 0.01) 
Vitality ρ = −0.247 (p 
< 0.05) 
Mental Health ρ = 
−0.208 (p < 0.05) 
Social functioning ρ = 
−0.426 (p < 0.01) 
Bodily pain ρ = 
−0.351 (p < 0.01) 
General Health NS 
Pooled or summary result (overall rating) 138  0.805 96  0.806 96  
FIQ: ρ = 0.304 (p < 
0.01) 
SF-36: General 
Health NS 
Social functioning ρ = 
−0.426 (p < 0.01) 
KMO: Kaiser-Meyer-Olkin, ρ: Spearman’s rank correlation coefficient, FIQ: Fibromyalgia Impact Questionnaire, SF-36: Short-Form health survey-36, NS: nonsignificant. 
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Table 6. Results of studies on measurement properties (JSS). 
PROM (Ref) 
Country (Language) in Which the 
PROM Was Evaluated 
Internal Consistency Criterion validity Reliability Responsiveness 
n 
Meth 
Qual 
Result 
(Rating) 
n 
Meth 
Qual 
Result 
(Rating) 
n 
Meth 
Qual 
Result 
(Rating) 
n  
Meth 
Qual 
Results (Rating) 
Jenkins Sleep 
Scale [18] 
United States of America (English) 195 + α = 0.70 195 +/− 
FIQ item 16 r = 
0.68 
FIQ item 17 r = 
0.72 
Pain VAS r = 
54 
Fatigue VAS r 
= 57 
ESS r = 0.43 
FOSQ total 
score r =  
−0.57 
SF-36 Vitality 
score r =  
−0.66 
195 +/− 
FIQ total score 
ICC 0.70 
FIQ item 17 
ICC 0.72 
ESS  
ICC 0.69 
Fatigue VAS 
ICC 0.66 
Pain VAS  
ICC 0.61 
R: 38 
NR: 
115 
+ 
R: 
Pain VAS + FIQ 
total score 
SES = 1.62 
NR 
Pain VAS + FIQ 
total score 
SES = −1.33 
Pooled or summary result (overall rating) 195  0.70   0.43–0.72 195  0.61–0.72 
R: 38 
NR: 
115 
 
R: 1.62 
NR: −1.33 
r: Pearson Correlation Coefficient, ICC: Intraclass Correlation, α: Cronbach’s alpha, SES: Standardized effect sizes, FIQ: Fibromyalgia Impact Questionnaire, FOSQ: 
Functional Outcomes of Sleep Questionnaire, SF-36: Short-Form health survey-36, ESS: Epworth Sleepiness Scale, VAS: Visual Analogue Scale, R: Responders, NR: Non-
responders. 
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Table 7. Results of studies on measurement properties (SQ-NRS). 
PROM (Ref) 
Country (Language) in Which 
the PROM Was Evaluated 
Criterion Validity Test–Retest Reliability  Responsiveness 
n 
Meth 
Qual 
Result (Rating) n 
Meth 
Qual 
Result 
(Rating) 
n 
Meth 
Qual 
Result 
(Rating) 
Sleep Quality 
Numeric Rating Scale 
[20] 
United States of America 
(English) 
Sample 1 
= 748 
Sample 2 
= 745 
+ 
PNRS 
Sample 1 r = 0.64, p < 0.001 
Sample 2 r = 0.58, p < 0.001 
MOS-SS 
Sample 1 
Sleep disturbance r = 0.45, p < 
0.001 
Snoring r = 0.01, p = 0.884 
Awaken Short of breath of with 
headache r = 0.21, p < 0.001 
Quantity of sleep r = −0.31, p < 
0.001 
Sleep adequacy r = −0.21, p < 
0.001 
Somnolence r = 0.11, p = 0.004 
Sample 2 
Sleep disturbance r = 0.42, p < 
0.001 
Snoring r = 0.00, p = 0.993 
Awaken Short of breath of with 
headache r = 0.14, p < 0.001 
Quantity of sleep r = −0.34, p < 
0.001 
Sleep adequacy r = −0.32, p < 
0.001 
Somnolence r = 0.15, p < 0.001 
Sample 1 
= 748 
Sample 2 
= 745 
+ 
Sample 1 
ICC 0.90 
Sample 2 
ICC 0.91 
Pregabalin 
treatment 
Sample 1: 
300mg (n = 
368) 
Sample 2: 
450mg (n = 
373) 
Sample 3: 
600mg (n = 
378) 
+ 
Sample 1: 
SES = 0.46–
0.52 
Sample 2: 
SES = 0.59 
Sample 3: 
SES = 0.73 
Pooled or summary result (overall rating) 1493  
PNRS 0.58–0.64 
MOS-SS 0.00–0.45 
1493  0.90–0.91   0.46–0.73 
PNRS: Pain Numerical Rating Scale, MOS-SS: Medical Outcomes Measures-Sleep Scale, r: Pearson Correlation Coefficient, ICC: Intraclass Correlation. 
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Table 8. Results of studies on measurement properties (MOS-SS). 
PROM (ref) 
Country (Language) in Which 
the PROM Was Evaluated 
Structural Validity Internal Consistency Test–Retest Reliability  
n 
Meth 
Qual 
Result (Rating) n 
Meth 
Qual 
Result (Rating) n 
Meth 
Qual 
Result 
(Rating) 
Medical Outcomes 
Study Sleep Scale [20] 
United States of America 
(English) 
Sample 1 = 
748 
Sample 2 = 
745 
− 
CFA 
Bentler’s 
comparative fit 
index 
Baseline: 0.88 
Week 5: 0.93 
Week 9: 0.91 
Week 13: 0.92 
Sample 1 = 
748 
Sample 2 = 
745 
+/− 
Sample 1: 
Week 1/week 13 
Sleep disturbance subscale 
α = 0.78/α = 0.87 
Somnolence subscale α = 
0.72/α = 0.86 
Sleep adequacy subscale α 
= 0.36/α = 0.74 
Sample 2:  
Week 1/week 13 
Sleep disturbance subscale 
α = 0.80/α = 0.87  
Somnolence subscale α = 
0.71/α = 0.75 
Sleep adequacy subscale α 
= 0.61/α = 0.74 
   
Medical Outcomes 
Study Sleep Scale [21] 
United States of America 
(English) 
      140 + 
Week 1 =  
ICC 0.81 
Week 4 =  
ICC 0.89 
Pooled or summary result (overall rating) 1493  0.88–0.93 1493  0.36–0.87  140  0.81–0.89 
CFA: Confirmatory Factor Analysis, α: Cronbach’s alpha, ICC: Intraclass Correlation. 
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4. Discussion 
This systematic review aimed to describe the available PROMs for assessing sleep quality in 
people diagnosed with FM and to present and analyze their psychometric properties. A total of seven 
studies [17–23] and five PROMs were included in this systematic review: (1) Pittsburgh Sleep Quality 
Index, (2) Jenkins Sleep Scale, (3) Sleep Quality Numeric Rating Scale, (4) Medical Outcomes Study-
Sleep Scale, and (5) Fibromyalgia Sleep Diary. All of the included studies presented low RoB for the 
analyzed psychometric properties according to the COSMIN RoB checklist, indicating very good 
methodological quality [15]. Likewise, the quality of the results ranged from moderate to high in 
accordance with the established COSMIN standards [12]. Although not all of the included studies 
conducted an analysis of the content validity of the PROMs, this systematic review found that the 
concept of sleep quality in the context of FM is homogeneous across included studies.  
The PSQI showed high quality results for internal consistency, test–retest reliability, and 
hypotheses testing. For the JSS, the results were high quality for internal consistency and 
responsiveness and moderate for criterion validity and test–retest reliability as some of the items 
analyzed did not achieve the minimum pre-established standards. The SQ-NRS showed high quality 
for content validity, criterion validity, test–retest reliability, and responsiveness. For the MOS-SS, the 
results for structural validity, content validity, internal consistency, and test–retest reliability were 
rated as high quality. With regard to the FSD, the authors analyzed only the content validity, which 
demonstrated high quality results. Therefore, the PSQI, the JSS, the SQ-NRS, and the MOS-SS present 
satisfactory psychometric properties and are valid and reliable tools for assessing sleep quality in the 
context of FM.  
Interestingly, the FSD is the only PROM specifically developed for evaluating sleep quality in 
patients with FM and is also the only one in which the psychometric properties were not analyzed. 
The latter highlights the need for future studies investigating if the FSD is a valid and reliable PROM 
in the context of FM. 
In the context of clinical practice, the SQ-NRS is likely the most adequate measure for a rapid 
visual analogue scale-format evaluation of global severity of poor sleep quality, due to time restraints 
that usually accompany healthcare practice [28,29]. However, because the subjective perception of 
poor sleep quality in people diagnosed with FM is associated with alterations to different aspects of 
sleep (e.g., problems falling and staying asleep), tools allowing for a more comprehensive assessment 
of those sleep aspects could provide valuable information on how poor sleep quality impacts the 
general health of patients with FM and guide the development of more individualized treatment 
approaches. The PSQI, the JSS, and the MOS-SS permit the assessment of various components of sleep 
during the month prior to their completion, which provides concrete information on those aspects of 
sleep that are most affected. 
At the research level, using valid and reliable PROMs for sleep quality in the context of FM could 
improve the quality of the studies’ results and increase knowledge of the relationship between poor 
sleep quality and other FM symptoms. Moreover, when investigating new treatment approaches, 
using PROMs for sleep quality that have been validated in people with FM could provide more 
reliable conclusions about their effectiveness [9]. Although the SQ-NRS is as valid and reliable as the 
other included PROMs, using tools such as the PSQI, the JSS, and the MOS-SS which permit a more 
comprehensive evaluation of sleep quality, could provide more accurate information on the effects 
of new interventions on specific sleep quality aspects and how these aspects relate with other FM 
symptoms. In this regard, the PSQI is the most widely used PROM among the existing literature in 
the field of FM, providing relevant information about both the relationship of poor sleep quality to 
other symptoms of this health condition [30–33] and the effects of different treatment approaches [34–
37]. 
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5. Conclusions 
In conclusion, this systematic review revealed that the available PROMs for assessing sleep 
quality in people diagnosed with FM are valid and reliable. However, this subject remains a vital 
field of research as none of the included studies reported the complete list of psychometric properties 
established in the COSMIN guidelines [12]. In particular, the FSD, which is the only PROM 
specifically developed for people diagnosed with FM, should be analyzed for its validity and 
reliability.  
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Appendix A 
Search strategy from the consulted databases. 
Appendix A1. Pubmed 
(“Sleep”[Mesh] OR “Sleep Hygiene”[Mesh] OR “Sleep”[tiab] OR “DIMS”[TIAB]) AND 
(“Fibromyalgia”[Mesh] OR Fibromyalgia*[TIAB] OR “Muscular Rheumatism”[TIAB] OR 
Fibrositi*[TIAB]) AND (instrumentation[sh] OR methods[sh] OR “Validation Studies”[pt] OR 
“Comparative Study”[pt] OR “psychometrics”[MeSH] OR psychometr*[tiab] OR clinimetr*[tw] OR 
clinometr*[tw] OR “outcome assessment (health care)”[MeSH] OR “outcome assessment”[tiab] OR 
“outcome measure*”[tw] OR “observer variation”[MeSH] OR “observer variation”[tiab] OR “Health 
Status Indicators”[Mesh] OR “reproducibility of results”[MeSH] OR reproducib*[tiab] OR 
“discriminant analysis”[MeSH] OR reliab*[tiab] OR unreliab*[tiab] OR valid*[tiab] OR “coefficient of 
variation”[tiab] OR coefficient[tiab] OR homogeneity[tiab] OR homogeneous[tiab] OR “internal 
consistency”[tiab] OR (cronbach*[tiab] AND (alpha[tiab] OR alphas[tiab])) OR (item[tiab] AND 
(correlation*[tiab] OR selection*[tiab] OR reduction*[tiab])) OR agreement[tw] OR precision[tw] OR 
imprecision[tw] OR “precise values”[tw] OR test-retest[tiab] OR (test[tiab] AND retest[tiab]) OR 
(reliab*[tiab] AND (test[tiab] OR retest[tiab])) OR stability[tiab] OR interrater[tiab] OR inter-
rater[tiab] OR intrarater[tiab] OR intra-rater[tiab] OR intertester[tiab] OR inter-tester[tiab] OR 
intratester[tiab] OR intra-tester[tiab] OR interobserver[tiab] OR inter-observer[tiab] OR 
intraobserver[tiab] OR intra-observer[tiab] OR intertechnician[tiab] OR inter-technician[tiab] OR 
intratechnician[tiab] OR intra-technician[tiab] OR interexaminer[tiab] OR inter-examiner[tiab] OR 
intraexaminer[tiab] OR intra-examiner[tiab] OR interassay[tiab] OR inter-assay[tiab] OR 
intraassay[tiab] OR intra-assay[tiab] OR interindividual[tiab] OR inter-individual[tiab] OR 
intraindividual[tiab] OR intra-individual[tiab] OR interparticipant[tiab] OR inter-participant[tiab] 
OR intraparticipant[tiab] OR intra-participant[tiab] OR kappa[tiab] OR kappa’s[tiab] OR 
kappas[tiab] OR repeatab*[tw] OR ((replicab*[tw] OR repeated[tw]) AND (measure[tw] OR 
measures[tw] OR findings[tw] OR result[tw] OR results[tw] OR test[tw] OR tests[tw])) OR 
generaliza*[tiab] OR generalisa*[tiab] OR concordance[tiab] OR (intraclass[tiab] AND 
correlation*[tiab]) OR discriminative[tiab] OR “known group”[tiab] OR “factor analysis”[tiab] OR 
“factor analyses”[tiab] OR “factor structure”[tiab] OR “factor structures”[tiab] OR dimension*[tiab] 
OR subscale*[tiab] OR (multitrait[tiab] AND scaling[tiab] AND (analysis[tiab] OR analyses[tiab])) 
OR “item discriminant”[tiab] OR “interscale correlation*”[tiab] OR error[tiab] OR errors[tiab] OR 
“individual variability”[tiab] OR “interval variability”[tiab] OR “rate variability”[tiab] OR 
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(variability[tiab] AND (analysis[tiab] OR values[tiab])) OR (uncertainty[tiab] AND 
(measurement[tiab] OR measuring[tiab])) OR “standard error of measurement”[tiab] OR 
sensitiv*[tiab] OR responsive*[tiab] OR (limit[tiab] AND detection[tiab]) OR “minimal detectable 
concentration”[tiab] OR interpretab*[tiab] OR ((minimal[tiab] OR minimally[tiab] OR clinical[tiab] 
OR clinically[tiab]) AND (important[tiab] OR significant[tiab] OR detectable[tiab]) AND 
(change[tiab] OR difference[tiab])) OR (small*[tiab] AND (real[tiab] OR detectable[tiab]) AND 
(change[tiab] OR difference[tiab])) OR “meaningful change”[tiab] OR “ceiling effect”[tiab] OR “floor 
effect”[tiab] OR “Item response model”[tiab] OR IRT[tiab] OR Rasch[tiab] OR “Differential item 
functioning”[tiab] OR DIF[tiab] OR “computer adaptive testing”[tiab] OR “item bank”[tiab] OR 
“cross-cultural equivalence”[tiab]) NOT (‘delphi-technique’[ti] OR cross-sectional[ti] OR 
“addresses”[Publication Type] OR “biography”[Publication Type] OR “case reports”[Publication 
Type] OR “comment”[Publication Type] OR “directory”[Publication Type] OR 
“editorial”[Publication Type] OR “festschrift”[Publication Type] OR “interview”[Publication Type] 
OR “lectures”[Publication Type] OR “legal cases”[Publication Type] OR “legislation”[Publication 
Type] OR “letter”[Publication Type] OR “news”[Publication Type] OR “newspaper 
article”[Publication Type] OR “patient education handout”[Publication Type] OR “popular 
works”[Publication Type] OR “congresses”[Publication Type] OR “consensus development 
conference”[Publication Type] OR “consensus development conference, nih”[Publication Type] OR 
“practice guideline”[Publication Type]) NOT (“animals”[MeSH Terms] NOT “humans”[MeSH 
Terms]). 
Appendix A2. CINAHL Plus 
Table A1. CINAHL Plus. 
# Query Results 
S1 (MH “Sleep Hygiene”) OR (MH “Sleep”) 17.544 
S2 TI Sleep OR AB sleep 54.713 
S3 (MH “Fibromyalgia”) 5.285 
S4 
TI (Fibromyalgia* OR “Muscular Rheumatism” OR Fibrositi*) OR AB 
(Fibromyalgia* OR “Muscular Rheumatism” OR Fibrositi*) 
5.299 
S5 S1 OR S2 59.549 
S6 S3 OR S4 6.382 
S7 S5 AND S6 732 
S8 
(MH “Psychometrics”) or (TI psychometr* or AB psychometr*) or (TI 
clinimetr* or AB clinimetr*) or (TI clinometr* OR AB clinometr*) or (MH 
“Outcome Assessment”) or (TI outcome assessment or AB outcome 
assessment) or (TI outcome measure* or AB outcome measure*) or (MH 
“Health Status Indicators”) or (MH “Reproducibility of Results”) or (MH 
“Discriminant Analysis”) or ((TI reproducib* or AB reproducib*) or (TI 
reliab* or AB reliab*) or (TI unreliab* or AB unreliab*)) or ((TI valid* or AB 
valid*) or (TI coefficient or AB coefficient) or (TI homogeneity or AB 
homogeneity)) or (TI homogeneous or AB homogeneous) or (TI “coefficient 
of variation” or AB “coefficient of variation”) or (TI “internal consistency” or 
AB “internal consistency”) or (MH “Internal Consistency+”) or (MH 
“Reliability+”) or (MH “Measurement Error+”) or (MH “Content Validity+”) 
or “hypothesis testing” or “structural validity” or “cross-cultural validity” 
568.245 
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or (MH “Criterion-Related Validity+”) or “responsiveness” or 
“interpretability” or (TI reliab* or AB reliab*) and ((TI test or AB test) OR (TI 
retest or AB retest)) or (TI stability or AB stability) or (TI interrater or AB 
interrater) or (TI inter-rater or AB inter-rater) or (TI intrarater or AB 
intrarater) or (TI intra-rater or AB intrarater) or (TI intertester or AB 
intertester) or (TI inter-tester or AB inter-tester) or (TI intratester or AB 
intratester) or (TI intra-tester or AB intra-tester) or (TI interobserver or AB 
interobserver) or (TI inter-observer or AB inter-observer) or (TI 
intraobserver or AB intraobserver) or (TI intra-observer or AB intra-
observer) or (TI intertechnician or AB intertechnician) or (TI inter-technician 
or AB inter-technician) or (TI intratechnician or AB intratechnician) or (TI 
intra-technician or AB intra-technician) or (TI interexaminer or AB 
interexaminer) or (TI inter-examiner or AB inter-examiner) or (TI 
intraexaminer or AB intraexaminer) OR (TI intra-examiner or AB intra-
examiner) or (TI intra-examiner or AB intraexaminer) or (TI interassay or AB 
interassay) or (TI inter-assay or AB inter-assay) or (TI intraassay or AB 
intraassay) or (TI intra-assay or AB intra-assay) or (TI interindividual or AB 
interindividual) or (TI inter-individual or AB inter-individual) OR (TI 
intraindividual or AB intraindividual) or (TI intra-individual or AB intra-
individual) or (TI interparticipant or AB interparticipant) or (TI inter-
participant or AB inter-participant) or (TI intraparticipant or AB 
intraparticipant) or (TI intra-participant or AB intra-participant) or (TI kappa 
or AB kappa) or (TI kappa’s or AB kappa’s) or (TI kappas or AB kappas) or 
(TI repeatab* or AB repeatab*) or (TI responsive* or AB responsive*) or (TI 
interpretab* or AB interpretab*) 
S9 S7 AND S8 150 
Appendix A3. Scopus 
TITLE-ABS-KEY ((“Sleep” OR “DIMS”) AND (fibromyalgia* OR “Muscular Rheumatism” OR 
fibrositi*) AND (psychometr* OR clinimetr* OR clinometr* OR “outcome assessment” OR “outcome 
measure*” OR “observer variation” OR reproducib* OR reliab* OR unreliab* OR valid* OR 
“coefficient of variation” OR coefficient OR homogeneity OR homogeneous OR “internal 
consistency” OR (cronbach* AND (alpha OR alphas)) OR (item AND (correlation* OR selection* OR 
reduction*)) OR agreement OR precision OR imprecision OR “precise values” OR test-retest OR (test 
AND retest) OR (reliab* AND (test OR retest)) OR stability OR interrater OR inter-rater OR intrarater 
OR intra-rater OR intertester OR inter-tester OR intratester OR intra-tester OR interobserver OR inter-
observer OR intraobserver OR intra-observer OR intertechnician OR inter-technician OR 
intratechnician OR intra-technician OR interexaminer OR inter-examiner OR intraexaminer OR intra-
examiner OR interassay OR inter-assay OR intraassay OR intra-assay OR interindividual OR inter-
individual OR intraindividual OR intra-individual OR interparticipant OR inter-participant OR 
intraparticipant OR intra-participant OR kappa OR kappa’s OR kappas OR repeatab* OR ((replicab* 
OR repeated) AND (measure OR measures OR findings OR result OR results OR test OR tests)) OR 
generaliza* OR generalisa* OR concordance OR (intraclass AND correlation*) OR discriminative OR 
“known group” OR “factor analysis” OR “factor analyses” OR “factor structure” OR “factor 
structures” OR dimension* OR subscale* OR (multitrait AND scaling AND (analysis OR analyses)) 
OR “item discriminant” OR “interscale correlation*” OR error OR errors OR “individual variability” 
OR “interval variability” OR “rate variability” OR (variability AND (analysis OR values)) OR 
(uncertainty AND (measurement OR measuring)) OR “standard error of measurement” OR sensitiv* 
OR responsive* OR (limit AND detection) OR “minimal detectable concentration” OR interpretab* 
OR ((minimal OR minimally OR clinical OR clinically) AND (important OR significant OR detectable) 
AND (change OR difference)) OR (small* AND (real OR detectable) AND (change OR difference)) 
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OR “meaningful change” OR “ceiling effect” OR “floor effect” OR “Item response model” OR irt OR 
rasch OR “Differential item functioning” OR dif OR “computer adaptive testing” OR “item bank” 
OR “cross-cultural equivalence”)). 
Appendix A4. Psychinfo 
((MAINSUBJECT.EXACT(“Sleep”) OR MAINSUBJECT.EXACT(“Insomnia”) OR 
MAINSUBJECT.EXACT(“Sleep Wake Disorders”) OR MAINSUBJECT.EXACT.EXPLODE(“Sleep”)) 
OR tiab(sleep OR dims)) AND (MAINSUBJECT.EXACT(“Fibromyalgia”) OR tiab(fibromyalgia* OR 
fibrositi* OR “muscular rheumatism*”)) AND (cl(“Psychometrics & Statistics & Methodology” OR 
“Research Methods & Experimental Design”) OR (psychometr* OR clinimetr* OR clinometr* OR 
“outcome assessment” OR “outcome measure*” OR  “observer variation” OR reproducib* OR reliab* 
OR unreliab* OR valid* OR coefficient OR homogeneity OR homogeneous OR  “internal consistency” 
OR agreement OR precision OR imprecision OR “precise values” OR test-retest OR reliab* OR 
stability OR interrater OR inter-rater OR intrarater OR intra-rater OR intertester OR inter-tester OR 
intratester OR intra-tester OR interobserver OR inter-observer OR intraobserver OR intra-observer 
OR intertechnician OR inter-technician OR intratechnician OR intra-technician OR interexaminer OR 
inter-examiner OR intraexaminer OR intra-examiner OR interassay OR inter-assay OR intraassay OR 
intra-assay OR interindividual OR inter-individual OR intraindividual OR intra-individual OR 
interparticipant OR inter-participant OR intraparticipant OR intra-participant OR kappa* OR 
repeatab* OR generaliza* OR generalisa* OR concordance OR discriminative OR “known group” OR 
“factor analys*” OR dimension* OR subscale* OR “item discriminant” OR “interscale correlation*” 
OR error* OR “individual variability” OR “standard error of measurement” OR sensitiv* OR 
responsive* OR “meaningful change” OR “Item response model” OR IRT OR Rasch OR “Differential 
item functioning” OR DIF OR  “computer adaptive testing” “item bank” OR “Cross-cultural 
equivalence” OR “Ceiling effect” OR “floor effect”) OR (“cronbach* alpha*” OR “replicab* test*” OR 
“repeated measure” OR “repeated measurement” OR “repeated measurements” OR “repeated 
measures” OR “repeated finding” OR “repeated result*” OR “repeated testing” OR “repeated tests” 
OR “item correlation*” OR “item selection” OR “item reduction*” OR “Test retest” OR “intraclass 
correlation” OR “multitrait scaling analys*” OR “uncertainty measur*” OR “variability analys*” OR 
“variability value*” OR “minimal* important change” OR “minimal* important difference” OR 
“minimal* significant change” OR “minimal* significant difference” OR “minimal* significant 
change” OR “minimal* significant difference” OR “minimal* detectable change” OR “minimal* 
detectable difference” OR “clinical* important change” OR “clinical* important difference” OR 
“clinical* significant change” OR “clinical* significant difference” OR “clinical* detectable change” 
OR “clinical detectable difference” OR “small* real change” OR “small* real difference” OR “small* 
detectable change” OR “small* detectable difference”) OR SU.EXACT.EXPLODE(“Error Analysis”) 
OR SU.EXACT.EXPLODE(“Measurement”) OR SU.EXACT.EXPLODE(“Factor Analysis”) OR 
SU.EXACT.EXPLODE(“Statistical Reliability”) OR SU.EXACT.EXPLODE(“Factor Structure”) OR 
SU.EXACT.EXPLODE(“Testing Methods”) OR SU.EXACT.EXPLODE(“Consistency 
(Measurement)”) OR SU.EXACT.EXPLODE(“Test Construction”) OR 
SU.EXACT.EXPLODE(“Interrater Reliability”) OR SU.EXACT.EXPLODE(“Error of Measurement”) 
OR SU.EXACT.EXPLODE(“Statistical Validity”) OR SU.EXACT.EXPLODE(“Prediction”) OR 
SU.EXACT.EXPLODE(“Content Analysis”) OR SU.EXACT.EXPLODE(“Prediction Errors”) OR 
SU.EXACT.EXPLODE(“Computerized Assessment”)). 
Appendix A5. ISI Web of Science 
TS = ((“Sleep” OR “DIMS”) AND (fibromyalgia* OR “Muscular Rheumatism” OR fibrositi*) 
AND (psychometr* OR clinimetr* OR clinometr* OR “outcome assessment” OR “outcome measure*” 
OR “observer variation” OR reproducib* OR reliab* OR unreliab* OR valid* OR “coefficient of 
variation” OR coefficient OR homogeneity OR homogeneous OR “internal consistency” OR 
(cronbach* AND (alpha OR alphas)) OR (item AND (correlation* OR selection* OR reduction*)) OR 
agreement OR precision OR imprecision OR “precise values” OR test-retest OR (test AND retest) OR 
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(reliab* AND (test OR retest)) OR stability OR interrater OR inter-rater OR intrarater OR intra-rater 
OR intertester OR inter-tester OR intratester OR intra-tester OR interobserver OR inter-observer OR 
intraobserver OR intra-observer OR intertechnician OR inter-technician OR intratechnician OR intra-
technician OR interexaminer OR inter-examiner OR intraexaminer OR intra-examiner OR interassay 
OR inter-assay OR intraassay OR intra-assay OR interindividual OR inter-individual OR 
intraindividual OR intra-individual OR interparticipant OR inter-participant OR intraparticipant OR 
intra-participant OR kappa OR kappa’s OR kappas OR repeatab* OR ((replicab* OR repeated) AND 
(measure OR measures OR findings OR result OR results OR test OR tests)) OR generaliza* OR 
generalisa* OR concordance OR (intraclass AND correlation*) OR discriminative OR “known group” 
OR “factor analysis” OR “factor analyses” OR “factor structure” OR “factor structures” OR 
dimension* OR subscale* OR (multitrait AND scaling AND (analysis OR analyses)) OR “item 
discriminant” OR “interscale correlation*” OR error OR errors OR “individual variability” OR 
“interval variability” OR “rate variability” OR (variability AND (analysis OR values)) OR 
(uncertainty AND (measurement OR measuring)) OR “standard error of measurement” OR sensitiv* 
OR responsive* OR (limit AND detection) OR “minimal detectable concentration” OR interpretab* 
OR ((minimal OR minimally OR clinical OR clinically) AND (important OR significant OR detectable) 
AND (change OR difference)) OR (small* AND (real OR detectable) AND (change OR difference)) 
OR “meaningful change” OR “ceiling effect” OR “floor effect” OR “Item response model” OR irt OR 
rasch OR “Differential item functioning” OR dif OR “computer adaptive testing” OR “item bank” 
OR “cross-cultural equivalence”)) OR TI = ((“Sleep” OR “DIMS”) AND (fibromyalgia* OR “Muscular 
Rheumatism” OR fibrositi*) AND (psychometr* OR clinimetr* OR clinometr* OR “outcome 
assessment” OR “outcome measure*” OR “observer variation” OR reproducib* OR reliab* OR 
unreliab* OR valid* OR “coefficient of variation” OR coefficient OR homogeneity OR homogeneous 
OR “internal consistency” OR (cronbach* AND (alpha OR alphas)) OR (item AND (correlation* OR 
selection* OR reduction*)) OR agreement OR precision OR imprecision OR “precise values” OR test-
retest OR (test AND retest) OR (reliab* AND (test OR retest)) OR stability OR interrater OR inter-
rater OR intrarater OR intra-rater OR intertester OR inter-tester OR intratester OR intra-tester OR 
interobserver OR inter-observer OR intraobserver OR intra-observer OR intertechnician OR inter-
technician OR intratechnician OR intra-technician OR interexaminer OR inter-examiner OR 
intraexaminer OR intra-examiner OR interassay OR inter-assay OR intraassay OR intra-assay OR 
interindividual OR inter-individual OR intraindividual OR intra-individual OR interparticipant OR 
inter-participant OR intraparticipant OR intra-participant OR kappa OR kappa’s OR kappas OR 
repeatab* OR ((replicab* OR repeated) AND (measure OR measures OR findings OR result OR results 
OR test OR tests)) OR generaliza* OR generalisa* OR concordance OR (intraclass AND correlation*) 
OR discriminative OR “known group” OR “factor analysis” OR “factor analyses” OR “factor 
structure” OR “factor structures” OR dimension* OR subscale* OR (multitrait AND scaling AND 
(analysis OR analyses)) OR “item discriminant” OR “interscale correlation*” OR error OR errors OR 
“individual variability” OR “interval variability” OR “rate variability” OR (variability AND (analysis 
OR values)) OR (uncertainty AND (measurement OR measuring)) OR “standard error of 
measurement” OR sensitiv* OR responsive* OR (limit AND detection) OR “minimal detectable 
concentration” OR interpretab* OR ((minimal OR minimally OR clinical OR clinically) AND 
(important OR significant OR detectable) AND (change OR difference)) OR (small* AND (real OR 
detectable) AND (change OR difference)) OR “meaningful change” OR “ceiling effect” OR “floor 
effect” OR “Item response model” OR irt OR rasch OR “Differential item functioning” OR dif OR 
“computer adaptive testing” OR “item bank” OR “cross-cultural equivalence”)). 
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